Project Grant HT9425261E440
Award Date 8/15/26
Completion Date 8/14/28
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77021, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $1.4 million Project Grant on September 16, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support translational therapeutics research focused on accelerating the discovery and clinical application of cancer treatments, with particular emphasis on pancreatic cancer. The three-year award, extending through September 2029, funds basic and applied biomedical research...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, through September 30, 2028. The award supports research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of therapeutic T-cell immunotherapy...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $560K Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2028. The award supports research on modulating hypoxia-activated stromal programs to potentiate chimeric antigen receptor T (CAR-T) cell therapy in kidney cancer. This project directly aligns with the DHA's mission to advance biomedical solutions for Service...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,431,215 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded October 1, 2025, with a completion date of September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $490,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The grant funds research combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition to develop novel immunotherapy approaches for pancreatic...
- Federal Grant Award Summary Award Details: The Sloan-Kettering Institute for Cancer Research received a $1.39M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with performance extending through August 31, 2029. The award supports an integrated immunomodulatory analysis of LAG3 (Lymphocyte-Activation Gene 3) inhibition in renal cell carcinoma (RCC), a hypothesis-driven research initiative addressing...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $559,998 Project Grant on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on therapeutic targeting of RNA processing to enhance anti-melanoma immunotherapy. The two-year project, concluding May 31, 2028, supports investigator-initiated biomedical research designed to advance medical solutions relevant to Service Member...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park (doing business as Health Research At Roswell Park) received a $4.2 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2030. The award funds a first-in-human clinical trial of CD83 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory acute myeloid leukemia (AML), conducted at the organization's...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $559,997 Project Grant to The University of Texas MD Anderson Cancer Center for research on novel immunotherapeutic targeting of Fc Epsilon Receptor II/CD23 for CD23-positive hematologic and solid tumor malignancies. The award, issued September 1, 2026, with completion targeted for August 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This research initiative supports the...